Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.
复制标题
DOI：
10.1186/bcr1783
复制
发表时间：
2007
期刊：
影响因子：
--
通讯作者：
Uhr J
中科院分区：
文献类型：
--
作者：
Fehm T;Becker S;Duerr-Stoerzer S;Sotlar K;Mueller V;Wallwiener D;Lane N;Solomayer E;Uhr J
在确定转移性疾病时，如果在首次诊断时未确定HER2状态，并且在疾病进展过程中获得HER2阳性，则评估人表皮生长因子受体（HER）2状态可能有助于优化治疗决策。在这种背景下，血清HER2的测定或循环肿瘤细胞（ctc）中HER2状态的评估可能具有临床相关性，因为转移组织可能由于其定位而难以获得用于分析。因此，本研究的目的是确定原发性肿瘤HER2阴性或HER2状态未知的转移性乳腺癌患者血清中HER2的状态和相应的ctc。77例HER2状态为阴性（n = 44）或未知（n = 33）的转移性乳腺癌患者的血液样本。血清HER2采用商用HER2/neu ELISA试剂盒检测。ctc采用免疫磁富集的载玻片法检测，并通过表型和基因分型进行表征。或者，基于RT-PCR的商业试剂盒用于检测和表征ctc。77例转移性疾病患者中有20例血清HER2水平升高。对67例患者的血液样本进行了ctc分析。21例可检测到ctc的患者中有8例表现出HER2扩增。使用至少一种方法，77例患者中有23例HER2阳性。21例患者中有15例（71%）ctc的HER2状态与血清HER2状态一致。在6例患者中获得了相互矛盾的结果。3例血清HER2水平升高的患者为HER2阴性CTCs，而3例HER2阳性CTCs患者血清HER2水平正常。最初HER2状态为阴性或未知的患者亚组在转移性疾病发展时可能出现血清HER2水平升高和/或HER2阳性ctc。虽然只研究了少数患者，但我们的观察结果具有临床相关性，因为目前这些患者无法获得her2靶向治疗。
At the time when metastatic disease is identified, assessment of human epidermal growth factor receptor (HER)2 status might help to optimize treatment decisions if HER2 status was not determined at first diagnosis and if HER2 positivity has been acquired during disease progression. Within this context, determination of serum HER2 or evaluation of HER2 status in circulating tumor cells (CTCs) may be of clinical relevance because metastatic tissue may be difficult to obtain for analysis as a result of its localization. The aim of this study was therefore to determine the HER2 status in serum and corresponding CTCs in patients with metastatic breast cancer whose primary tumors were HER2 negative or of unknown HER2 status. Blood samples were obtained from 77 metastatic breast cancer patients with negative (n = 44) or unknown (n = 33) HER2 status. Serum HER2 was determined using a commercial HER2/neu ELISA kit. CTCs were detected by slide-based assay using immunomagnetic enrichment and characterized by phenotyping and genotyping. Alternatively, a commercial kit, based on RT-PCR, was used to detect and characterize CTCs. Twenty out of 77 patients with metastatic disease had elevated serum levels of HER2. Blood samples could be analyzed for the presence of CTCs in 67 patients. Eight out of 21 patients with detectable CTCs exhibited HER2 amplification. Twenty-three out of 77 patients were HER2 positive using at least one method. Concordance between HER2 status of CTCs and serum HER2 was observed in 15 of 21 patients (71%). In six patients conflicting results were obtained. Three patients with elevated serum HER2 status had HER2-negative CTCs, whereas three patients with HER2-positive CTCs had normal serum HER2 levels. A subgroup of patients with initially negative or unknown HER2 status can have elevated serum HER2 levels and/or HER2-positive CTCs at the time of development of metastatic disease. Although only a small number of patients were studied, our observations are of clinical relevance because, currently, these patients do not have access to HER2-targeted therapy.
登录
查看更多内容
影响因子：
158.5
作者：
Cristofanilli, M;Budd, GT;Hayes, DF
通讯作者：
Hayes, DF
影响因子：
11.5
作者：
Hayes, Daniel F.;Cristofanilli, Massimo;Terstappen, Leon W. W. M.
通讯作者：
Terstappen, Leon W. W. M.
影响因子：
45.3
作者：
Moliterni, A;Ménard, S;Bonadonna, G
通讯作者：
Bonadonna, G
影响因子：
56.9
作者：
COUSSENS, L;YANGFENG, TL;ULLRICH, A
通讯作者：
ULLRICH, A
DOI：
10.1093/jnci/95.2.142
发表时间：
2003-01-15
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
Konecny, G;Pauletti, G;Slamon, DJ
通讯作者：
Slamon, DJ